SNDX - CIK 0001395937
Syndax Pharmaceuticals Inc (SNDX) reported revenue of $172.35M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $172.35M | +627.8% |
| FY 2024 | $23.68M | - |
| FY 2023 | $0.00 | - |
| FY 2022 | $0.00 | -100.0% |
| FY 2021 | $139.71M | +9109.6% |
| FY 2020 | $1.52M | +0.0% |
| FY 2019 | $1.52M | +0.0% |
| FY 2018 | $1.52M | -28.0% |
| FY 2017 |
Syndax Pharmaceuticals Inc (SNDX) reported revenue of $172.35M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, Syndax Pharmaceuticals Inc's revenue grew from $627.00K to $172.35M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.11M |
| +72.8% |
| FY 2016 | $1.22M | +94.6% |
| FY 2015 | $627.00K | - |